Inhibrx | Investors - News Releases

News Releases

Month Year

Month Year

Dec 1, 2021

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

- Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma
Nov 9, 2021

Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
Nov 3, 2021

Inhibrx Announces Presentations at SITC 2021
Nov 1, 2021

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences
Oct 28, 2021

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors
Sep 13, 2021

Inhibrx Announces Participation in Upcoming Investor Conference
Aug 9, 2021

Inhibrx Reports Second Quarter 2021 Financial Results
Jun 21, 2021

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford

- Median progression-free survival (PFS) of 7.6 months and disease control rate of 87.5% observed in conventional chondrosarcoma patients in Phase 1
May 17, 2021

Inhibrx Announces Participation in Upcoming Investor Conferences
May 13, 2021

Inhibrx Reports First Quarter 2021 Financial Results

Show per page

Back To Top